Leap Therapeutics Inc - רווח נקי למניה בארבעת הרבעונים האחרונים LPTX

The annual EPS TTM YoY trend for Leap Therapeutics, Inc. (LPTX) demonstrates the resilience of its gastric cancer therapy patents, which create a defensive barrier. However, the high cost of rare tumor trials and FDA safety requirements remain significant risks. The -15.20 metric confirms the current level, while dependence on Asian supplies and logistics determines the overall stability of the business.
LPTX (Leap Therapeutics Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The development of innovative immunotherapeutic treatments for gastrointestinal cancer places Leap Therapeutics, Inc. (LPTX) in the category of high-risk assets with potential for exponential growth. By analyzing the YoY ttm earnings per share growth chart, an investor assesses the net income dynamics over the year, which allows for a comparison of current business efficiency against market capitalization and determines the company's stage of fundamental development.